How to Sell Your Veterinary Practice in 2026

Last year, I represented a veterinary practice owner in what should have been a straightforward sale. Three-location emergency and specialty practice in the Midwest. Clean books. Strong associate team. The kind of practice corporate buyers fight over.

The first offer came in at $14.2 million. The owner-we'll call him Dr. Miller-was thrilled. His broker had estimated $11-12M. This was 20% above expectations.

Then Dr. Miller made a mistake that cost him $2.3 million.

He signed the Letter of Intent without attorney review. It looked standard. Exclusivity period. Due diligence timeline. Purchase price. What he missed: the working capital peg was set $400K below his historical average. The earnout calculation used a formula that excluded his highest-margin service line. The employment agreement terms locked him in for three years at 40% below market.

By the time I got involved, the terms were "agreed." The buyer's position: "We negotiated this in good faith. We're not re-opening closed issues."

Dr. Miller netted $11.9 million on a $14.2M headline price. The gap wasn't fraud. It was leverage-leverage he gave away before he understood what he was agreeing to.

I'm an M&A attorney. I've closed dozens of veterinary practice transactions. I don't broker deals, and I don't take commissions on sale prices. What follows is what I tell clients when they're considering selling-the unvarnished reality that brokers won't explain because it complicates their pitch.

The veterinary M&A market has shifted. If you're still working from 2021-2022 expectations-when practices traded at 14-18x EBITDA and buyers waived due diligence-you're in for a rude awakening.

Here's the current reality based on Q1 2025 transaction data:

The Consolidation Wave Continues-But Differently

Corporate veterinary is still acquiring. Mars Veterinary (which owns VCA and Banfield) remains the largest player. NVA and Pathway continue building their portfolios. But the strategy has shifted from "acquire everything" to "acquire strategically."

What this means for sellers:

• Premium multiples require premium practices. Generic GP clinics without differentiation are seeing compressed multiples.
• Geographic clustering matters. Buyers pay more for practices that fit existing footprints.
• Associate retention is critical. A practice dependent on a departing owner is worth significantly less.
• Specialty services command premiums. Dental, orthopedic, and oncology capabilities add 1-3 multiple turns.

The SVP/MVP mega-merger in late 2024 closed at 17-18x EBITDA, signaling that premium assets still command premium prices. But that deal involved massive scale and strategic synergies unavailable to single-practice owners.

Every seller wants to know: "What's my practice worth?" The honest answer is uncomfortable: your practice is worth whatever a qualified buyer will pay for it. Everything else is educated guessing.

That said, valuations follow predictable formulas. Understanding them helps you negotiate from knowledge, not hope.

The EBITDA Calculation

EBITDA-Earnings Before Interest, Taxes, Depreciation, and Amortization-is the standard metric. But veterinary practice EBITDA requires significant adjustments:

A critical warning: Sellers routinely overstate adjusted EBITDA by 15-25%. Buyers will normalize it during due diligence. If your broker's valuation relies on aggressive add-backs, you're setting yourself up for a painful repricing mid-transaction.

What Adds Value (And What Doesn't)

EBITDA Margin Benchmarks

A healthy veterinary practice EBITDA margin runs 13-16% of revenue. Most small practices average 11-12%. If your margin exceeds 18%, you'll receive premium offers. Below 10%? Buyers will question whether the practice is sustainable.

Understanding buyer motivations changes how you negotiate. Each buyer type has different priorities, timeline pressures, and deal structures. Knowing this gives you leverage.

Corporate Consolidators

Major Players: Mars Veterinary (VCA, Banfield, BluePearl), NVA, Pathway Vet Alliance, Thrive Pet Healthcare

What they want: Scale. They're building regional density to reduce overhead, share specialists, and create referral networks. They pay premium multiples for practices that fit existing clusters.

Typical offer: 12-16x EBITDA for practices with >$1M EBITDA. Mostly cash at closing with 10-20% in earnouts. Employment agreements for 2-3 years post-close.

The catch: Corporate deals come with corporate constraints. You'll report to regional managers. Pricing decisions won't be yours. Many sellers struggle with loss of autonomy even when the money is right.

Private Equity Platforms

Examples: KKR-backed platforms, Blackstone affiliates, various PE portfolio companies

What they want: A platform to build upon, or add-ons to an existing platform. They're financial engineers-they'll optimize operations, add practices, and sell in 3-5 years for a higher multiple.

Typical offer: 8-12x for platform acquisitions (larger practices), 6-8x for add-ons. Often require rollover equity (you keep 10-30% ownership in the combined entity).

The opportunity: Rollover equity can be lucrative if the platform executes well. You might get a second bite when they sell to the next buyer. The risk: you're betting on their execution with illiquid equity.

Regional Groups

What they want: Geographic expansion within their existing footprint. They're building 3-10 practice clusters before eventually selling to corporate or PE.

Typical offer: 8-10x EBITDA. More flexibility on terms than corporate. Often willing to structure creative deals for the right practice.

The advantage: More personal relationship. They understand veterinary medicine (often founded by veterinarians). Transition periods tend to be smoother.

Individual Buyers (Associate DVMs)

What they want: Practice ownership. Independence. Building equity instead of earning a salary.

Typical offer: 5-7x EBITDA for smaller practices. Heavy reliance on SBA financing (typically 10% down, 10-year amortization). Often include seller financing components.

The reality check: Individual buyers can't match corporate multiples. But they may be ideal for solo practices that corporates don't want. Transaction processes tend to be slower due to financing contingencies.

The headline purchase price is what brokers market and sellers celebrate. The deal structure is what determines how much you actually take home. I've seen $12M deals net the same as $9M deals because of structure differences.

Asset Purchase vs. Stock Purchase

Asset purchases represent 90%+ of veterinary practice transactions. The buyer acquires specific assets (equipment, client records, goodwill) rather than buying your corporate entity.

Why buyers prefer asset deals:

• Stepped-up tax basis on acquired assets (more depreciation)
• No inherited liabilities (unknown lawsuits, tax issues)
• Cleaner transition

Why sellers sometimes want stock deals:

• C-corps face double taxation on asset sales (corporate level + shareholder level)
• Capital gains treatment on stock sale vs. ordinary income on some asset allocations

The negotiation: If you're structured as a C-corp, the asset vs. stock discussion can shift hundreds of thousands in tax liability. This is where having a competent M&A attorney and CPA working together pays for itself many times over.

Earnouts: The Hidden Trap

An earnout defers a portion of the purchase price based on post-closing performance. In veterinary deals, earnouts typically represent 10-25% of total value, paid over 1-3 years.

What to negotiate in earnouts:

• Linear payment (pro-rata for achievement) vs. cliff (all-or-nothing)
• Clear definitions of included/excluded revenue and expenses
• Protection against buyer actions that reduce achievability
• Dispute resolution mechanism with independent accountant
• Acceleration triggers if buyer sells the practice during earnout period

Working Capital Adjustments

Working capital adjustments are where sophisticated buyers extract value. The concept is simple: the practice needs a certain level of working capital to operate, and the seller should deliver that at closing.

The trap: Buyers set the "target" working capital below your historical average, then adjust the purchase price downward at closing when actuals come in higher. I've seen $200K-$400K swings on working capital alone.

The defense: Negotiate the working capital peg based on trailing twelve-month average, not a buyer-selected period. Include collars (floors and caps) on adjustments. Ensure the calculation methodology is crystal clear.

Rollover Equity

PE buyers often require sellers to "roll" 10-30% of proceeds into equity in the acquiring entity. This aligns incentives and signals seller confidence.

The opportunity: If the platform executes well, your rollover equity can multiply when they exit to the next buyer in 3-5 years.

The risk: Illiquid investment. No guaranteed exit. Your returns depend on management you no longer control. I've seen rollovers return 3x original value and others go to zero.

What to negotiate: Tag-along rights (you can sell when they sell). Valuation methodology for future transactions. Information rights (quarterly financials). Drag-along protections (you can't be forced to sell at unfair prices).

Employment Agreements and Non-Competes

Most corporate buyers require sellers to stay 2-3 years post-closing. The employment terms can significantly impact your effective proceeds.

Employment considerations:

• Salary: Many buyers offer 30-50% below market, reasoning that you got your premium in the sale price
• Production bonuses: Can add $100K+ annually if structured correctly
• Schedule flexibility: Often negotiable even when salary isn't
• Termination provisions: "For cause" definitions matter enormously

Non-compete terms: Standard is 2-3 years within 10-25 miles. These are generally enforceable in most states. Negotiate the scope carefully-some agreements prohibit even providing veterinary advice within the restricted area.

I've said it before: the LOI is where sellers lose deals. Not because the deal falls apart, but because they lock in unfavorable terms without realizing it.

Here's the dynamic: Buyers know that once you sign an LOI, you're emotionally committed. You've told your staff. Maybe your family. You're mentally checked out of running the practice. They have leverage you no longer possess.

What Most Sellers Don't Understand About LOIs

An LOI contains both binding and non-binding provisions. The problem? Sellers assume more is non-binding than actually is.

But here's the catch: even "non-binding" terms create anchoring. Once you've "agreed" to a working capital peg or an earnout structure, buyers will treat any seller attempt to improve terms as bad faith renegotiation.

The 7 LOI Terms to Negotiate Before Signing

1. Purchase price adjustment mechanism: What triggers adjustments? How are they calculated? What's the floor?
2. Working capital target: Based on what period? What's included/excluded? What's the collar on adjustments?
3. Earnout structure: Metrics, calculation methodology, payment timing, acceleration triggers, dispute resolution
4. Exclusivity period: How long? What terminates it early? Can you continue preliminary discussions with others?
5. Due diligence scope: What are they entitled to review? When can they access employees and clients?
6. Termination rights: What allows either party to walk? What are the consequences?
7. Employment terms: Compensation, duration, termination provisions, non-compete scope

Due diligence is where deals die or get repriced. The buyer's team will spend 30-60 days examining every aspect of your practice. What they find-and don't find-determines whether the price holds.

What Buyers Actually Look For

Buyers run due diligence through multiple lenses:

Documents You Need Ready

Start assembling these before going to market:

• 3 years tax returns (corporate and personal if pass-through)
• Monthly P&L statements (24 months minimum)
• Bank statements (12 months, all accounts)
• Accounts receivable aging report
• Patient/client count by year
• All employee agreements and compensation details
• Real estate lease (with all amendments)
• Equipment list with age and condition
• Insurance policies and claims history
• DEA registration and state licenses

→ Read our complete guide on what happens after you sign the LOI

The tax implications of selling your practice can swing your net proceeds by 15-25%. This is not an area to wing it.

Entity Structure Matters

S-Corp or LLC (pass-through): In an asset sale, gain flows through to your personal return. Portion allocated to equipment may be taxed as ordinary income (depreciation recapture). Portion allocated to goodwill typically receives capital gains treatment.

C-Corp: Asset sales create potential double taxation-corporate level on the sale, then shareholder level when distributing proceeds. Stock sales avoid this but buyers resist them. The structure needs planning well before sale.

Purchase Price Allocation

How the purchase price is allocated between asset classes affects both parties' taxes. Buyers want to allocate to depreciable assets (faster write-offs). Sellers often want allocation to goodwill (capital gains).

The allocation is negotiable, but must be reasonable and consistently applied by both parties on their tax returns.

Transition Period Considerations

Most buyers require a transition period where you remain involved. Consider:

• Duration: 2-3 years is standard for corporate buyers
• Schedule: Often negotiable from full-time to part-time
• Compensation: Usually below your historical earnings as owner
• Exit triggers: What happens if it's not working?

The transition period is about more than money. I've seen sellers miserable for three years because they negotiated aggressively on price but didn't think about what it would be like to work for someone else in "their" practice.

Non-Compete Agreements

Non-competes are standard and generally enforceable in veterinary sales. Typical terms:

• Duration: 2-3 years (sometimes 5 for premium sales)
• Geographic scope: 10-25 mile radius
• Scope: Veterinary services generally, sometimes specific restrictions

Tax note: Amounts allocated to non-compete agreements are taxed as ordinary income. Buyers sometimes want higher allocation to non-competes for faster amortization. Sellers usually resist this.

Expect 6-12 months from decision to close. Trying to rush typically costs money-either in lower price or worse terms.

→ Download our detailed post-LOI milestone tracker

The answer is: earlier than you think. And probably not the attorney you use for other business matters.

The "Too Late" Mistake

Most sellers engage M&A counsel after signing the LOI, when the purchase agreement shows up. By then, the key economic terms are "agreed" and your leverage is minimal.

The broker's standard advice: "We'll get the lawyers involved after the LOI." This benefits the broker (faster deals, less complication) but not you.

When to Actually Engage

• Before you hire a broker: Review the engagement agreement. Broker commissions and exclusive terms are negotiable-but only before you sign.
• Before you receive LOIs: Know what terms to push on before offers arrive.
• During LOI negotiation: This is where the value is. The purchase agreement mostly documents what was agreed in the LOI.
• Throughout due diligence: Issues arise. Having counsel who understands the deal prevents small problems from becoming big ones.

What M&A Counsel Actually Does

Unlike your business lawyer who reviews leases and employment matters, M&A counsel:

• Understands deal dynamics and buyer strategies
• Knows which terms matter and which don't
• Has negotiated against the same buyers before
• Can coordinate tax planning with your CPA
• Manages the due diligence process efficiently